Inj. lorazepam IM
| Parameter | Lorazepam |
|---|---|
| Absorption (IM) | Well absorbed; reliable |
| Peak plasma level (IM) | ~90 min |
| Protein binding | 90-98% |
| Lipid solubility | Moderate (accounts for slower brain uptake vs. midazolam) |
| Elimination half-life | ~15 h |
| Metabolism | Hepatic glucuronidation (no active metabolites) |
| Excretion | Urine |
Note: Diazepam IM is painful and unreliably absorbed - lorazepam IM is preferred when IV access is unavailable. Midazolam peaks faster (30 min IM).
- Morgan & Mikhail's Clinical Anesthesiology, 7e
| Indication | Dose | Route |
|---|---|---|
| Acute agitation (monotherapy) | 2-4 mg | IM |
| Acute agitation (with antipsychotic) | 2 mg | IM |
| Status epilepticus | 0.1 mg/kg (max 4 mg), repeat once if needed | IV preferred; IM if no IV |
| Alcohol withdrawal seizure | 2 mg | IV/IM |
| Premedication | 0.05 mg/kg | Oral/IM |
| Delirium (as adjunct) | 0.5-5 mg | IM |
| System | Effect |
|---|---|
| Respiratory | Dose-dependent respiratory depression; apnea possible (esp. with IV/opioid co-administration) |
| CNS | Excessive sedation, anterograde amnesia, ataxia |
| Cardiovascular | Mild BP/CO reduction; hypotension (more with opioid combination) |
| Paradoxical | Disinhibition, agitation (rare) |
| Delirium | Can worsen delirium (use with caution in non-alcohol delirium) |
Ventilation must be monitored in all patients receiving benzodiazepines IV; resuscitation equipment and airway-trained personnel must be present.
- Morgan & Mikhail's Clinical Anesthesiology, 7e